Alnylam’s heart drug troubles take center stage at a cardiology conference
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Alnylam’s heart drug troubles take center stage at a cardiology conference" is generating significant coverage in the Business category, with 9 articles from 7 distinct sources tracked by PULSE so far.
Outlets currently covering the story include HCPLive, BioSpace, Seeking Alpha and STAT. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 79d ago.
Quick answers
Why is "Alnylam’s heart drug troubles take center stage at a cardiology conference" trending?
Because 7 independent news sources published 9 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (9)
- CARDIO-TTRansform: Eplontersen Misses Primary Endpoint in ATTR-CM HCPLive · 83d ago
- ‘Worse than expected’ Wainua data muddies water for TTR silencers BioSpace · 83d ago
- Alnylam drops as AstraZeneca posts full trial results for failed heart drug Seeking Alpha · 83d ago
- AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching STAT · 83d ago
- Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A Biotech Leader with 56.72% Potential Upside DirectorsTalk Interviews · 83d ago
- Is Alnylam (ALNY) Turning Expanded HELIOS-B and Zilebesiran Data Into Durable Cardiovascular Leadership? Yahoo Finance · 83d ago
- Future of AstraZeneca’s gene silencer in heart disease uncertain after trial failure Endpoints News · 83d ago
- In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs STAT · 83d ago
- Alnylam’s heart drug troubles take center stage at a cardiology conference STAT · 83d ago
Topics
Related trends
Record diesel prices drive UK inflation to 1-year high of 3.6%
Gold Steadies Near 14-Month Low as Rate-Hike Pressure Mounts
Here’s how much Medicare Part B premiums are rising in 2027
The Centers for Medicare & Medicaid Services announced that the standard Medicare Part B premium will increase by 3.2% for 2027.